Safety, Tolerability and Efficacy of HAVAI, for Correction of Inter-metatarsal Angle

Multi Center, Open-label, Single Arm, Study Designed to Evaluate Safety, Tolerability and Efficacy of HAVAI, a Minimally Invasive Implant Composed of Spring, Double Anchor and Suture, Versus Standard of Care 1st Metatarsal Osteotomy, for Correction of Inter-metatarsal Angle in Subjects Suffering From Hallux Valgus Deformity

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02831868

Enrollment

Registered

2016-07-13

Start date

2018-03-01

Completion date

2019-12-31

Last updated

2018-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hallux Valgus

Brief summary

A non-inferiority study to demonstrate efficacy of the HAVAI minimally invasive device compared to standard of surgical care 1st metatarsal osteotomy (SSOC)

Interventions

DEVICEHAVAI

implantation of the HAVAI device to correct the IMA angle

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Adult males and female subjects, aged 20 to 75 years old, inclusive, at screening visit. 2. Subject weighing \<100 kg and body mass index (BMI) \<32 kg/m2. 3. Subjects with confirmed diagnosis of HV deformity based on radiography assessment of IMA 12°-15°. 4. Able and willing to comply with the requirements of the protocol. 5. Able to understand and sign written informed consent to participate in the study.

Exclusion criteria

1. Patients who need or may need to have 2nd MT osteotomy as part of their index surgery (e.g. instability or subluxation of 2nd MTPJ) 2. History of: a. Severe Diabetes mellitus (defined as existence of: i. More than 10 years duration ii. HbA1C 8.0 \< iii. any known complications of diabetes (PVD, Nephropathy \[CR\>1.3\], retinopathy, IHD)) b. Claudication, known peripheral vascular disease or no palpable pulses (DP or TP). c. Known rheumatoid or inflammatory disease. d. X-ray evidence of moderate osteoarthritis of MTPJ-1 or TMTJ-1. e. neurological conditions associated with spasticity or lower limb paralysis. f. Prior operation on MT1 or MT2. g. Fracture (past or present) of MT1 or MT2. 3. Aseptic necrosis or any deformity of MT2 head. 4. Aseptic necrosis of the MT1 head 5. Pregnant women or women with childbearing potential who are not obliged to take any contraception measures 6. Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or subject is receiving other investigational agent(s) 7. ASA grade above 2

Design outcomes

Primary

Measure	Time frame	Description
A change in IMA angle	50 weeks	A change in IMA angle - compared to baseline using t test for repeated measures with 0.05 significance level.

Countries

Israel

Contacts

Primary ContactDaniel Billig, MBA

dbillig@bonfixmedical.com02-6553333

Backup ContactAyelet Goldwasser, CTA

ayelet@duet-medical.com052-5771144

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026